cd20 car-t
Recurrent or Refractory B Cell Malignancy
Shanghai Longyao Biotechnology Inc., Ltd.Cell therapyPhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
317 Active assets in the Recurrent or Refractory B Cell Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINDESINE Children's Cancer Group, China | Phase 4 | BBB |
cc-5013 Shanghai Junshi Bioscience Co., Ltd. | Phase 4 | BBB |
Odronextamab University of Birmingham | Phase 3 | BBB |
METHOTREXATE Children's Cancer Group, China | Phase 4 | BBB |
Cytosin-Arabinosid Children's Cancer Group, China | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
cd20 car-t is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →